Clinical trials: Attention-Deficit and Hyperactivity Disorder
- Condition Attention-Deficit and Hyperactivity Disorder
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder, Substance Use Disorders
CBT for Patients With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders
The purpose of this study is to determine if cognitive behavioral therapy is effective in treating ADHD symptoms in patients with substance use disorders and comorbid ADHD.
- Trial name
- NCT01431235
- Testing
- cognitive behavioral therapy for treating ADHD symptoms
- Where
- Netherlands
- Volunteers
- 184 people
- Sponsor
- Arkin
Attention Deficit Hyperactivity Disorder (ADHD)
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12…
- Trial name
- NCT01835548
- Testing
- NT0102
- Where
- 4 sites in United States
- Volunteers
- 87 people
- Sponsor
- Neos Therapeutics, Inc
Attention Deficit Hyperactivity Disorder
Standardized Lycium Chinense Fruit Extract Enhances Attention and Cognitive Function in Healthy Young People
Lycium chinense fruit (LCF) is widely distributed in East Asia that has been used traditionally for anti-aging purposes. This study was performed to examine the effects of LCF on attention and cognitive function in healthy young…
- Trial name
- NCT03439111
- Testing
- Standardized Lycium chinense Fruit Extract (LCF) capsules
- Where
- South Korea
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Biomix
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and efficacy of Osmotic Release Oral System (OROS) methylphenidate in participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT01012622
- Testing
- Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
- Volunteers
- 142 people
- Sponsor
- Janssen Korea, Ltd., Korea
Attention Deficit Disorder With Hyperactivity (ADHD)
Healing Minds II: Biofeedback, Breathing Practices, Nutrition and Exercise Counseling in Children and Adolescents With ADHD
The Pediatric Healing Minds II intervention includes a biofeedback component, breathing practices nutrition and exercise counseling.
- Trial name
- NCT07180602
- Testing
- Heart Math Biofeedback Breathing Practices, Nutrition Counseling combined with Exercise Counseling
- Where
- United States
- Sponsor
- Hoskinson Health and Wellness Clinic
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT01259492
- Testing
- Ritalin LA 20 mg, Ritalin LA 30 mg
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 725 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Disorder With Hyperactivity
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
This is a randomized, double-blind, placebo-controlled, parallel-group study of NFC-1 versus placebo in adolescents with ADHD who have genetic disorders impacting mGluRs.
- Trial name
- NCT02777931
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Adult Attention Deficit Hyperactivity Disorder
Dasotraline Adult ADHD Study
This is a randomized, double blind, multicenter, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in adults with ADHD.
- Trial name
- NCT02276209
- Testing
- Dasotraline
- Where
- 59 sites in United States
- Volunteers
- 636 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Disorder With Hyperactivity
Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)
The survey is designed to identify non-compliant Attention Deficit Hyperactivity Disorder (ADHD) patients who are currently on Immediate- Released Methylphenidate (IR-MPH) and observe any change in compliance after treating with…
- Trial name
- NCT00460720
- Testing
- Observational treatment compliance survey
- Volunteers
- 591 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a two-arm, parallel, randomized, double-blind, placebo-controlled Phase 4 multicenter trial to compare the whole day efficacy of atomoxetine versus placebo in children aged 6 through 12 years with…
- Trial name
- NCT00546910
- Testing
- Atomoxetine
- Where
- 16 sites in Germany
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Attention-deficit Hyperactivity Disorder (ADHD)
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
This trial is a Phase 1 study in adolescents with ADHD and genetic disruptions impacting genes in the metabotropic glutamate receptor (mGluR) network.
- Trial name
- NFC1-GREAT (NCT02286817)
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study were invited to participate in this study.
- Trial name
- NCT02691182
- Testing
- SPN-810
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Disorder With Hyperactivity
Safety of SPD465 in Treating Adults With ADHD.
The purpose of this study is to assess the safety and effectiveness of SPD465 in the treatment of ADHD. The study will also look at how SPD465 affects sleep.
- Trial name
- NCT00152035
- Testing
- Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.
- Volunteers
- 505 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents
To test the hypothesis that children/adolescents with ADHD, who are treated with atomoxetine hydrochloride in comparison to standard current therapies have greater improvements in their quality of life.
- Trial name
- NCT00191659
- Testing
- Atomoxetine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Dasotraline Pediatric Extension Study
This is an open label 26 week extension study for subjects who completed SEP360-202.
- Trial name
- NCT02457819
- Testing
- Dasotraline
- Where
- 36 sites in United States
- Volunteers
- 237 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder
Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
To assess the pharmacokinetics of a single dose of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules under fed conditions in male or female children 4 to under 6 years of age with ADHD.
- Trial name
- PK003 (NCT02470234)
- Testing
- Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
ADHD
Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo in adolescent subjects (13-17 years of age inclusive) with ADHD in the analog classroom setting based on the Permanent Product Measure…
- Trial name
- NCT01274221
- Testing
- SPD489
- Where
- 6 sites in United States
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder
Atomoxetine Hydrochloride Versus Placebo in Taiwanese Children and Adolescents With ADHD
The purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in Taiwanese children and adolescents with ADHD.
- Trial name
- NCT00485459
- Testing
- Atomoxetine Hydrochloride
- Where
- Taiwan
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company